Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) Shares Outstanding (Weighted Average) (2016 - 2025)

Haemonetics has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $47.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 5.55% year-over-year to $47.5 million; the TTM value through Dec 2025 reached $47.5 million, down 5.55%, while the annual FY2025 figure was $50.3 million, 0.74% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $47.5 million at Haemonetics, roughly flat from $47.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $51.2 million in Q3 2022 and troughed at $47.5 million in Q4 2025.
  • A 5-year average of $50.3 million and a median of $50.8 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 1.03% in 2021 and later dropped 6.5% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $51.0 million in 2021, then fell by 0.28% to $50.9 million in 2022, then fell by 0.25% to $50.8 million in 2023, then fell by 0.95% to $50.3 million in 2024, then decreased by 5.55% to $47.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for HAE at $47.5 million in Q4 2025, $47.6 million in Q3 2025, and $48.1 million in Q2 2025.